📣 VC round data is live. Check it out!
- Public Comps
- Niagen Bioscience
Niagen Bioscience Valuation Multiples
Discover revenue and EBITDA valuation multiples for Niagen Bioscience and similar public comparables like Medy-Tox, Zhejiang Shouxiangu, Grape King Bio, Tempo Scan Pacific and more.
Niagen Bioscience Overview
About Niagen Bioscience
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Founded
2000
HQ

Employees
104
Website
Financials (LTM)
EV
$330M
Valuation Multiples
Start free trialNiagen Bioscience Financials
Niagen Bioscience reported last 12-month revenue of $135M and EBITDA of $24M.
In the same LTM period, Niagen Bioscience generated $87M in gross profit, $24M in EBITDA, and $19M in net income.
Revenue (LTM)
Niagen Bioscience P&L
In the most recent fiscal year, Niagen Bioscience reported revenue of $129M and EBITDA of $16M.
Niagen Bioscience is profitable as of last fiscal year, with gross margin of 64%, EBITDA margin of 12%, and net margin of 13%.
Financial data powered by Morningstar, Inc.
Niagen Bioscience Stock Performance
Niagen Bioscience has current market cap of $392M, and enterprise value of $330M.
Market Cap Evolution
Niagen Bioscience's stock price is $4.92.
Niagen Bioscience share price increased by 4.3% in the last 30 days, and decreased by 54.5% in the last year.
Niagen Bioscience has an EPS (earnings per share) of $0.22.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $330M | $392M | 1.5% | 4.3% | -2.5% | -54.5% | $0.22 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNiagen Bioscience Valuation Multiples
Niagen Bioscience trades at 2.4x EV/Revenue multiple, and 14.1x EV/EBITDA.
EV / Revenue (LTM)
Niagen Bioscience Financial Valuation Multiples
As of May 5, 2026, Niagen Bioscience has market cap of $392M and EV of $330M.
Niagen Bioscience has a P/E ratio of 20.5x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Niagen Bioscience Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Niagen Bioscience Margins & Growth Rates
In the most recent fiscal year, Niagen Bioscience reported gross margin of 64%, EBITDA margin of 12%, and net margin of 13%.
Niagen Bioscience Margins
Niagen Bioscience Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Niagen Bioscience Operational KPIs
Niagen Bioscience's revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $0.7M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Niagen Bioscience Competitors
Niagen Bioscience competitors include Medy-Tox, Zhejiang Shouxiangu, Grape King Bio, Tempo Scan Pacific, Vita Life Sciences, Scitop Bio-tech, Venture Life Group, FitLife Brands, Enzymatica and Hofseth BioCare.
Most Niagen Bioscience public comparables operate across Nutraceuticals & Cosmeceuticals.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.9x | 2.9x | 26.4x | 25.0x | |||
| 4.6x | 4.6x | 13.5x | — | |||
| 1.2x | 1.2x | 4.4x | — | |||
| 0.5x | — | 3.5x | — | |||
| 1.1x | — | 6.7x | — | |||
| 10.9x | — | 28.8x | — | |||
| 1.3x | 1.0x | 8.2x | 6.1x | |||
| 1.6x | 1.5x | 12.6x | 9.1x | |||
This data is available for Pro users. Sign up to see all Niagen Bioscience competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Niagen Bioscience
| When was Niagen Bioscience founded? | Niagen Bioscience was founded in 2000. |
| Where is Niagen Bioscience headquartered? | Niagen Bioscience is headquartered in United States. |
| How many employees does Niagen Bioscience have? | As of today, Niagen Bioscience has over 104 employees. |
| Who is the CEO of Niagen Bioscience? | Niagen Bioscience's CEO is Robert N. Fried. |
| Is Niagen Bioscience publicly listed? | Yes, Niagen Bioscience is a public company listed on Nasdaq. |
| What is the stock symbol of Niagen Bioscience? | Niagen Bioscience trades under NAGE ticker. |
| When did Niagen Bioscience go public? | Niagen Bioscience went public in 2008. |
| Who are competitors of Niagen Bioscience? | Niagen Bioscience main competitors include Medy-Tox, Zhejiang Shouxiangu, Grape King Bio, Tempo Scan Pacific, Vita Life Sciences, Scitop Bio-tech, Venture Life Group, FitLife Brands, Enzymatica, Hofseth BioCare. |
| What is the current market cap of Niagen Bioscience? | Niagen Bioscience's current market cap is $392M. |
| What is the current revenue of Niagen Bioscience? | Niagen Bioscience's last 12 months revenue is $135M. |
| What is the current revenue growth of Niagen Bioscience? | Niagen Bioscience revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Niagen Bioscience? | Current revenue multiple of Niagen Bioscience is 2.4x. |
| Is Niagen Bioscience profitable? | Yes, Niagen Bioscience is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Niagen Bioscience? | Niagen Bioscience's last 12 months EBITDA is $24M. |
| What is Niagen Bioscience's EBITDA margin? | Niagen Bioscience's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Niagen Bioscience? | Current EBITDA multiple of Niagen Bioscience is 14.1x. |
| What is the current FCF of Niagen Bioscience? | Niagen Bioscience's last 12 months FCF is $20M. |
| What is Niagen Bioscience's FCF margin? | Niagen Bioscience's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Niagen Bioscience? | Current FCF multiple of Niagen Bioscience is 16.9x. |
| How many companies Niagen Bioscience has acquired to date? | Niagen Bioscience hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Niagen Bioscience has invested to date? | Niagen Bioscience hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Niagen Bioscience
Lists including Niagen Bioscience
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.